Time for a Heart-to-Heart: ADAPTing Antithrombotic Therapy Post-TAVR
Manage episode 343767452 series 2908322
Aeryana Beaudrie-Nunn, PharmD (Twitter: @ABeaudrieRx) identifies the rationale for antithrombotic therapy following TAVR, reviews the utility of direct oral anticoagulants after TAVR considering recent clinical trial data and defines the patient context where direct oral anticoagulant use following TAVR is most appropriate.
For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!
You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
101 jaksoa